IMPACT EBC: IMPlementing Advances in Cancer Treatment for Patients With HR+/HER2- Early Breast Cancer - Moving Patient Care Forward

IMPACT EBC: IMPlementing Advances in Cancer Treatment for Patients With HR+/HER2- Early Breast Cancer - Moving Patient Care Forward Approximately 30% of patients with early breast cancer (EBC) will eventually develop metastatic disease. In hormone receptor (HR)-positive breast cancer, approximately 50% of recurrences occurs within 5 years of diagnosis. Many factors should be considered when evaluating a patient's risk of recurrence, including HR status, and human epidermal growth factor receptor 2 (HER2) status, nodal involvement, histologic grade, anatomic stage, positive or close margins, proliferate rate, tumor size, and the patient's age and health status. IMPlementing Advances in Cancer Treatment for Patients With HR-Positive, HER2-Negative Early Breast Cancer is a collection of educational programs designed for clinicians to stay up to date on the clinical data that supports decision-making for patients with HR-positive, HER2-negative EBC at risk of recurrence and make an IMPACT on patient outcomes and quality of life. https://www.medscape.org/advances/implementing-advances-cancer-treatment-patients-hr-her2-2025a1000yzz